Michelle J. Henderson

Sydney, NSW, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 45 publications

BCL-2 and MCL1 co-inhibition enhances glucocorticoid therapy in preclinical models of infant KMT2A-rearranged acute lymphoblastic leukaemia.

BCL-2 and MCL1 co-inhibition enhances glucocorticoid therapy in preclinical models of infant KMT2A-rearranged acute lymphoblastic leukaemia.

Journal: British journal of haematology

Published: October 26, 2025

High Expression of NTRK1 in ETV6::RUNX1 Positive Acute Lymphoblastic Leukaemia Drives Factor Independence and Sensitivity to Larotrectinib.

High Expression of NTRK1 in ETV6::RUNX1 Positive Acute Lymphoblastic Leukaemia Drives Factor Independence and Sensitivity to Larotrectinib.

Journal: Pediatric blood & cancer

Published: August 28, 2025

Blinatumomab in de novo AYA ALL-Results of the Australasian Leukaemia and Lymphoma Group ALL09 "SUBLIME" study.

Blinatumomab in de novo AYA ALL-Results of the Australasian Leukaemia and Lymphoma Group ALL09 "SUBLIME" study.

Journal: HemaSphere

Published: July 23, 2025

Measurable Residual Disease detection in acute lymphoblastic leukaemia: comparison between targeted NGS and ASO-RQPCR.

Measurable Residual Disease detection in acute lymphoblastic leukaemia: comparison between targeted NGS and ASO-RQPCR.

Journal: Pathology

Published: May 18, 2025

The third generation AKR1C3-activated prodrug, ACHM-025, eradicates disease in preclinical models of aggressive T-cell acute lymphoblastic leukemia.

The third generation AKR1C3-activated prodrug, ACHM-025, eradicates disease in preclinical models of aggressive T-cell acute lymphoblastic leukemia.

Journal: Blood cancer journal

Published: September 08, 2024

Distinct pattern of genomic breakpoints in CML and BCR::ABL1-positive ALL: analysis of 971 patients.

Distinct pattern of genomic breakpoints in CML and BCR::ABL1-positive ALL: analysis of 971 patients.

Journal: Molecular cancer

Published: June 07, 2024

Diagnostic genomic analysis is prognostic in AYA patients with ALL treated on an MRD-stratified pediatric protocol.

Diagnostic genomic analysis is prognostic in AYA patients with ALL treated on an MRD-stratified pediatric protocol.

Journal: Blood neoplasia

Published: March 06, 2024

FDA-approved disulfiram as a novel treatment for aggressive leukemia.

FDA-approved disulfiram as a novel treatment for aggressive leukemia.

Journal: Journal of molecular medicine (Berlin, Germany)

Published: May 26, 2023

Suppression of the ABCA1 Cholesterol Transporter Impairs the Growth and Migration of Epithelial Ovarian Cancer.

Suppression of the ABCA1 Cholesterol Transporter Impairs the Growth and Migration of Epithelial Ovarian Cancer.

Journal: Cancers

Published: February 20, 2022

The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression.

The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression.

Journal: Frontiers in oncology

Published: January 27, 2022

Systematic In Vitro Evaluation of a Library of Approved and Pharmacologically Active Compounds for the Identification of Novel Candidate Drugs for KMT2A-Rearranged Leukemia.

Systematic In Vitro Evaluation of a Library of Approved and Pharmacologically Active Compounds for the Identification of Novel Candidate Drugs for KMT2A-Rearranged Leukemia.

Journal: Frontiers in oncology

Published: September 20, 2021

Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions.

Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions.

Journal: British journal of cancer

Published: September 17, 2021

Showing 1-12 of 45

Last Updated: 09/26/2026